Cationic Lipid Emulsion Adjuvant for Parenteral Immunization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunization methods using parenteral routes are often ineffective in inducing secretory IgA responses, and many antigens are poorly immunogenic when administered alone, requiring adjuvants to enhance immune responses, but these methods fail to induce robust immune responses when administered mucosally.
Innovation Solution
Formulating an injectable composition with a cationic lipid containing a polar head group and a dual chain hydrophobic component, such as dioctadecyl dimethyl ammonium chloride (DODAC), in an oil-in-water emulsion with a non-ionic surfactant and organic solvent, which induces robust immune responses when administered via injection but not mucosally.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If parenteral immunization methods are used to enhance immune response, then antigen-specific antibody responses are improved, but secretory IgA responses are not induced
Solution Approach 1:
The patent modifies the chemical composition parameters of the adjuvant system by using cationic lipids with specific head groups and hydrophobic components, creating an emulsion formulation that can adapt to different administration routes. This parameter change allows the same adjuvant to work effectively for both parenteral and mucosal routes, resolving the contradiction between reliable immune response and route flexibility.
2Reliability
If adjuvants are added to enhance immune response to poorly immunogenic antigens, then immune response is improved, but mucosal administration effectiveness deteriorates
Solution Approach 1:
The patent creates a composite adjuvant system combining cationic lipids, non-ionic surfactants, and organic solvents in an emulsion formulation. This composite material approach allows the adjuvant to function effectively for both parenteral and mucosal administration, eliminating the previous limitation where adjuvants enhanced immune response but failed for mucosal routes.
3Reliability
If traditional adjuvant formulations are used, then parenteral immunization effectiveness is improved, but formulation complexity for multi-route use increases
Solution Approach 1:
The patent develops a universal adjuvant formulation based on cationic lipid emulsions that can be administered through multiple routes (parenteral, intranasal, other mucosal routes) with effective immune response enhancement. This multi-functional formulation eliminates the need for route-specific formulations, reducing overall formulation complexity while maintaining effectiveness across different administration methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively induces antigen-specific antibody responses and Th1 cellular immune responses when administered intramuscularly, providing significant immune stimulation and protection against pathogens like RSV and influenza, while being ineffective when administered mucosally.
Implementation Method 1
Formulating an injectable composition with a cationic lipid containing a polar head group and a dual chain hydrophobic component, such as dioctadecyl dimethyl ammonium chloride (DODAC), in an oil-in-water emulsion with a non-ionic surfactant and organic solvent
Data Source
AI summary
The present invention provides compositions comprising emulsion adjuvant and one or more active agents or substances formulated for infusion or injection into a subject (e.g., using a syringe and needle), as well as methods of formulating and using the same (e.g., as an injectable medicinal composition (e.g., a vaccine)). The emulsion adjuvant of an immunogenic composition of the invention in its preferred form comprises a cationic lipid containing a polar head group and a hydrophobic component (e.g., a dual chain hydrophobic group (e.g., the cationic surfactant dioctadecyl dimethyl ammonium chloride (DODAC) and dioctadecyl dimethyl ammonium bromine (DODAB))). Compositions of the invention comprising emulsion adjuvant and one or more active agents or substances formulated for administration via injection to a subject find use in treatment and/or prevention of infectious disease, cancer and/or allergy.